ketorolac has been researched along with Retinal Diseases in 3 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to determine whether (-)-Epicatechin administered alone or simultaneously with topical Ketorolac decreased the relative expression of GFAP and modulated the response of Nrf2 in a mouse model with induced hyperglycemia." | 4.31 | Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice. ( Ceballos-Reyes, GM; Lima-Gómez, V; López-Mayorga, RM; Meaney-Mendiolea, E; Pérez-Cano, HJ; Rubio-Gayosso, AIO; Somilleda-Ventura, SA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Somilleda-Ventura, SA | 1 |
| López-Mayorga, RM | 1 |
| Meaney-Mendiolea, E | 1 |
| Rubio-Gayosso, AIO | 1 |
| Pérez-Cano, HJ | 1 |
| Ceballos-Reyes, GM | 1 |
| Lima-Gómez, V | 1 |
| Rodrigues, EB | 1 |
| Farah, ME | 1 |
| Bottós, JM | 1 |
| Bom Aggio, F | 1 |
| Heier, JS | 1 |
| Awh, CC | 1 |
| Busbee, BG | 1 |
| Waterbury, LD | 1 |
| Daniel, P | 1 |
| Stoller, GL | 1 |
| Cleary, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery[NCT02646072] | Phase 4 | 80 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ketorolac and Retinal Diseases
| Article | Year |
|---|---|
Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Bromobenzenes; Diclofenac | 2016 |
1 trial available for ketorolac and Retinal Diseases
| Article | Year |
|---|---|
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Be | 2009 |
1 other study available for ketorolac and Retinal Diseases
| Article | Year |
|---|---|
Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice.
Topics: Animals; Catechin; Hyperglycemia; Ketorolac; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Retin | 2023 |